Context Therapeutics is trading 5.41% up at $0.39 after-hours on September 18, 2026, with the move appearing mainly aligned with broader risk-on conditions.
- It follows the $0.37 regular-session close.
- No new company-specific announcement, earnings release, or regulatory catalyst was identified for September 18; the latest company update was the September 9 first-patient dosing announcement for CT-202.
- Nasdaq Composite gained 1.09% amid stronger technology-sector sentiment; trading activity appears limited, so recheck for delayed filings or news.